Form 4: Glycomimetics Insider Buys Shares
Insider Transaction (Form 4)
Fairmount Funds Management LLC and 3 others reported changes in beneficial ownership of Glycomimetics Inc common stock on July 16, 2026.
Summary
- Open-market purchase: acquired 853,450 Ordinary Shares at $14.50 ($12,375,025) on July 16, 2026; holds 3,601,316 after (Indirect).
- Open-market purchase: acquired 525,897 Pre-Funded Warrant (Right to Buy) at $14.50 ($7,624,981) on July 16, 2026; holds 2,294,037 after (Indirect).
Sentiment
Score: 9
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $20,000,006, committing personal capital to the stock.
Insider Transactions
Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Tomas Kiselak — Director, 10% owner
Peter Evan Harwin — Director, 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-16 | Open-market purchase | Ordinary Shares | 853,450 | $15 | $12.4M | 3,601,316 |
| 2026-07-16 | Open-market purchase | Pre-Funded Warrant (Right to Buy) | 525,897 | $14 | $7.6M | 2,294,037 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-16 | Open-market purchase (853,450 shares) |
| 2026-07-16 | Open-market purchase (525,897 shares) |
Keywords
insider transaction, Form 4, CBIO, CRESCENT BIOPHARMA, INC., bullish, Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, Peter Evan Harwin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.